SRDX - SurModics - Biotech IPO Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : SRDX - SurModics - Biotech IPO

SRDX 27.57

-2.0%

Apr 17 4:00 PM EDT

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

From: Lance Bredvold	11/6/2024 11:21:14 AM
	Read Replies (1) of 83

Another fine quarterly report with sales increasing nicely. I've continued to buy as the price declined to $37.50 assuming the FTC will approve the purchase of SRDX at $43 in the first quarter of 2025. Assuming that happens as predicted (by me) I'll earn $43/$37.70=14% for less than 6 months of the cash being tied up. Alternatively, if the FTC nixes the purchase I expect the price will drop significantly to perhaps $30 but recover as prospects for Pounce and the other products begin to show a profit. One surprise to me in reading through the entire SEC filing was to learn that SRDX had solicited a buyout and had evaluated several potential acquirers at lower prices before settling on GT??. I had assumed an acquirer had approached them with perhaps even a hostile offer. So another potential offer is unlikely. I'd thought it an unlikely happening, but that there would be a possibility. There are penalties on both sides for failing to follow through (roughly $20mm for SRDX, $50mm for GT??). May be my last post on this board.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next